Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- COV.AU
- Price
- 0.41
- Stock movement down
- -0.01 (-3.53%)
- Company name
- Cleo Diagnostics Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Medical Devices
- Market cap
- 52.69M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 10.81%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-30
DIVIDENDS
COV.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.42 |
| Daily high | 0.42 |
| Daily low | 0.41 |
| Daily Volume | 61K |
| All-time high | 0.55 |
| 1y analyst estimate | - |
| Beta | 0.67 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| COV.AU | S&P500 | |
| Current price drop from All-time high | -25.45% | -1.10% |
| Highest price drop | -39.09% | -19.00% |
| Date of highest drop | 28 Aug 2025 | 8 Apr 2025 |
| Avg drop from high | -26.67% | -2.76% |
| Avg time to new high | 67 days | 5 days |
| Max time to new high | 175 days | 89 days |
COMPANY DETAILS
Marketcap
52.69M
Marketcap category
Small-cap
Description
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company provides CleoDX pre-surgical triage tests which measures a combination of 5 biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property and patents. The company was incorporated in 2021 and is based in Melbourne, Australia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found